A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer | Journal of Experimental & Clinical Cancer Research | Full Text

A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer | Journal of Experimental & Clinical Cancer Research | Full Text

A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer

Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown ...

Authors:Yuexian Zhou, Huifang Zong, Lei Han, Yueqing Xie, Hua Jiang, John Gilly, Baohong Zhang, Huili Lu, Jie Chen, Rui Sun, Zhidi Pan and Jianwei Zhu

Citation:Journal of Experimental & Clinical Cancer Research 2020 39:87

Content type:Research

Published on: 12 May 2020

• ViewFull Text
 
• ViewPDF